Abstract
Background Selecting the most appropriate asthma therapy for individual patients can be challenging owing to limited data on real-life effectiveness of inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA) combinations available. Various factors, such as ease of use of the device and speed of onset of the LABA, can influence inhaler technique and adherence, thereby affecting clinical outcomes in real-life patients. Further studies are needed to evaluate whether efficacy of new asthma therapies demonstrated in clinical trials translate to effectiveness in a pragmatic setting.To compare the real-life effectiveness of switching to Flutiform® 250 (250 mcg fluticasone/10 mcg formoterol) from Seretide® 250 Evohaler® (250 mcg fluticasone/25 mcg salmeterol) in adult patients with asthma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
